The impact and cost-effectiveness of 9-valent human papillomavirus vaccine in adolescent females in Hong Kong View Full Text


Ontology type: schema:ScholarlyArticle      Open Access: True


Article Info

DATE

2021-11-20

AUTHORS

Tak Hong Cheung, Sally Shuk Yee Cheng, Danny C. Hsu, Queenie Wing-Lei Wong, Andrew Pavelyev, Anuj Walia, Kunal Saxena, Vimalanand S. Prabhu

ABSTRACT

IntroductionIn Hong Kong (HK), a single-cohort vaccination program for 10–12-year-old girls with the 9-valent human papillomavirus (HPV) vaccine (9vHPV; types 6/11/16/18/31/33/45/52/58) has been launched. This study assessed the public health impact and cost-effectiveness of implementing routine 9vHPV vaccination (12-year-olds) with or without catch-up 9vHPV vaccination (13–18-year-olds) in HK.MethodsThe health impact and costs of implementing routine 9vHPV vaccination with or without catch-up vaccination over a 100-year time horizon were evaluated using a validated HPV-type transmission dynamic model adapted to the HK population; analyses were performed from a healthcare payer perspective. Routine vaccination (12-year-old girls) and catch-up vaccination (13–18 years) assumed vaccine coverage rates of 70% (base case) and 30%, respectively. The model also assumed herd immunity, lifelong vaccine protection, a discount rate of 3%, and a cost per dose of HK dollars (HKD) 858 [United States dollars (USD) 110] and HKD 1390 (USD 179) for the 2-valent HPV (2vHPV) and 9vHPV vaccines, respectively. HPV disease-related incidence and the incremental cost-effectiveness ratio (ICER) per quality-adjusted-life-year (QALY) were estimated. Cost-effectiveness was determined at a ceiling threshold of HK dollars (HKD) 382,046 (USD 49,142) or 1.0 times the gross domestic product per capita of HK.ResultsCompared with routine 9vHPV alone, routine plus catch-up 9vHPV is projected to reduce cervical cancer incidence by 3.4%. Routine plus catch-up 9vHPV will also reduce genital warts incident cases for males/females by 2.6%/5.4%. The incremental cost-effectiveness ratios were HKD 29,911 (USD 3847)/quality-adjusted life-year (QALY) for routine plus catch-up 9vHPV versus routine 9vHPV alone and HKD 25,524 (USD 3283)/QALY for routine 9vHPV alone versus screening only. Sensitivity analyses indicated that routine plus catch-up 9vHPV compared with routine 9vHPV alone remained cost-effective at coverage rates of 30% and 90%.ConclusionsThis analysis predicts that the current HK vaccination strategy can be considered cost-effective and will provide maximum health benefit. These results support addition of the routine 9vHPV vaccine with or without catch-up 9vHPV vaccination to the regional vaccination program in HK. More... »

PAGES

75

Identifiers

URI

http://scigraph.springernature.com/pub.10.1186/s12962-021-00328-x

DOI

http://dx.doi.org/10.1186/s12962-021-00328-x

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1142712721

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/34801050


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/14", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Economics", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1402", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Applied Economics", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Department of Obstetrics and Gynecology, The Chinese University of Hong Kong, Hong Kong, People\u2019s Republic of China", 
          "id": "http://www.grid.ac/institutes/grid.10784.3a", 
          "name": [
            "Department of Obstetrics and Gynecology, The Chinese University of Hong Kong, Hong Kong, People\u2019s Republic of China"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Cheung", 
        "givenName": "Tak Hong", 
        "id": "sg:person.01371611151.45", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01371611151.45"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Global Medical and Scientific Affairs, MSD Asia Ltd, 27/F Lee Gardens Two, 28 Yun Ping Road, Causeway Bay, Hong Kong, People\u2019s Republic of China", 
          "id": "http://www.grid.ac/institutes/None", 
          "name": [
            "Global Medical and Scientific Affairs, MSD Asia Ltd, 27/F Lee Gardens Two, 28 Yun Ping Road, Causeway Bay, Hong Kong, People\u2019s Republic of China"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Cheng", 
        "givenName": "Sally Shuk Yee", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Global Medical and Scientific Affairs, MSD Asia Ltd, 27/F Lee Gardens Two, 28 Yun Ping Road, Causeway Bay, Hong Kong, People\u2019s Republic of China", 
          "id": "http://www.grid.ac/institutes/None", 
          "name": [
            "Global Medical and Scientific Affairs, MSD Asia Ltd, 27/F Lee Gardens Two, 28 Yun Ping Road, Causeway Bay, Hong Kong, People\u2019s Republic of China"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Hsu", 
        "givenName": "Danny C.", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Global Medical and Scientific Affairs, MSD Asia Ltd, 27/F Lee Gardens Two, 28 Yun Ping Road, Causeway Bay, Hong Kong, People\u2019s Republic of China", 
          "id": "http://www.grid.ac/institutes/None", 
          "name": [
            "Global Medical and Scientific Affairs, MSD Asia Ltd, 27/F Lee Gardens Two, 28 Yun Ping Road, Causeway Bay, Hong Kong, People\u2019s Republic of China"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Wong", 
        "givenName": "Queenie Wing-Lei", 
        "id": "sg:person.01352415670.11", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01352415670.11"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "HCL America, Inc., Sunnyvale, CA, USA", 
          "id": "http://www.grid.ac/institutes/None", 
          "name": [
            "MRL, Merck & Co., Inc., 2000 Galloping Hill Road, 07033, Kenilworth, NJ, USA", 
            "HCL America, Inc., Sunnyvale, CA, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Pavelyev", 
        "givenName": "Andrew", 
        "id": "sg:person.013611671644.98", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.013611671644.98"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "MRL, Merck & Co., Inc., 2000 Galloping Hill Road, 07033, Kenilworth, NJ, USA", 
          "id": "http://www.grid.ac/institutes/grid.417993.1", 
          "name": [
            "MRL, Merck & Co., Inc., 2000 Galloping Hill Road, 07033, Kenilworth, NJ, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Walia", 
        "givenName": "Anuj", 
        "id": "sg:person.011736111537.43", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.011736111537.43"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "MRL, Merck & Co., Inc., 2000 Galloping Hill Road, 07033, Kenilworth, NJ, USA", 
          "id": "http://www.grid.ac/institutes/grid.417993.1", 
          "name": [
            "MRL, Merck & Co., Inc., 2000 Galloping Hill Road, 07033, Kenilworth, NJ, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Saxena", 
        "givenName": "Kunal", 
        "id": "sg:person.013153105213.76", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.013153105213.76"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "MRL, Merck & Co., Inc., 2000 Galloping Hill Road, 07033, Kenilworth, NJ, USA", 
          "id": "http://www.grid.ac/institutes/grid.417993.1", 
          "name": [
            "MRL, Merck & Co., Inc., 2000 Galloping Hill Road, 07033, Kenilworth, NJ, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Prabhu", 
        "givenName": "Vimalanand S.", 
        "id": "sg:person.0725134162.11", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0725134162.11"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "sg:pub.10.1186/1471-2334-10-272", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1026945611", 
          "https://doi.org/10.1186/1471-2334-10-272"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1186/s12879-020-05632-0", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1134382708", 
          "https://doi.org/10.1186/s12879-020-05632-0"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1186/s12916-018-1118-3", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1105932555", 
          "https://doi.org/10.1186/s12916-018-1118-3"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2021-11-20", 
    "datePublishedReg": "2021-11-20", 
    "description": "IntroductionIn Hong Kong (HK), a single-cohort vaccination program for 10\u201312-year-old girls with the 9-valent human papillomavirus (HPV) vaccine (9vHPV; types 6/11/16/18/31/33/45/52/58) has been launched. This study assessed the public health impact and cost-effectiveness of implementing routine 9vHPV vaccination (12-year-olds) with or without catch-up 9vHPV vaccination (13\u201318-year-olds) in HK.MethodsThe health impact and costs of implementing routine 9vHPV vaccination with or without catch-up vaccination over a 100-year time horizon were evaluated using a validated HPV-type transmission dynamic model adapted to the HK population; analyses were performed from a healthcare payer perspective. Routine vaccination (12-year-old girls) and catch-up vaccination (13\u201318\u00a0years) assumed vaccine coverage rates of 70% (base case) and 30%, respectively. The model also assumed herd immunity, lifelong vaccine protection, a discount rate of 3%, and a cost per dose of HK dollars (HKD) 858 [United States dollars (USD) 110] and HKD 1390 (USD 179) for the 2-valent HPV (2vHPV) and 9vHPV vaccines, respectively. HPV disease-related incidence and the incremental cost-effectiveness ratio (ICER) per quality-adjusted-life-year (QALY) were estimated. Cost-effectiveness was determined at a ceiling threshold of HK dollars (HKD) 382,046 (USD 49,142) or 1.0 times the gross domestic product per capita of HK.ResultsCompared with routine 9vHPV alone, routine plus catch-up 9vHPV is projected to reduce cervical cancer incidence by 3.4%. Routine plus catch-up 9vHPV will also reduce genital warts incident cases for males/females by 2.6%/5.4%. The incremental cost-effectiveness ratios were HKD 29,911 (USD 3847)/quality-adjusted life-year (QALY) for routine plus catch-up 9vHPV versus routine 9vHPV alone and HKD 25,524 (USD 3283)/QALY for routine 9vHPV alone versus screening only. Sensitivity analyses indicated that routine plus catch-up 9vHPV compared with routine 9vHPV alone remained cost-effective at coverage rates of 30% and 90%.ConclusionsThis analysis predicts that the current HK vaccination strategy can be considered cost-effective and will provide maximum health benefit. These results support addition of the routine 9vHPV vaccine with or without catch-up 9vHPV vaccination to the regional vaccination program in HK.", 
    "genre": "article", 
    "id": "sg:pub.10.1186/s12962-021-00328-x", 
    "inLanguage": "en", 
    "isAccessibleForFree": true, 
    "isPartOf": [
      {
        "id": "sg:journal.1032048", 
        "issn": [
          "1478-7547"
        ], 
        "name": "Cost Effectiveness and Resource Allocation", 
        "publisher": "Springer Nature", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "1", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "19"
      }
    ], 
    "keywords": [
      "incremental cost-effectiveness ratio", 
      "human papillomavirus vaccine", 
      "cost-effectiveness ratio", 
      "papillomavirus vaccine", 
      "vaccination program", 
      "lifelong vaccine protection", 
      "regional vaccination program", 
      "cervical cancer incidence", 
      "vaccine coverage rates", 
      "healthcare payer perspective", 
      "public health impact", 
      "health impacts", 
      "transmission dynamic model", 
      "maximum health benefits", 
      "routine vaccination", 
      "vaccine protection", 
      "incident cases", 
      "vaccination strategies", 
      "cancer incidence", 
      "payer perspective", 
      "male/female", 
      "ConclusionsThis analysis", 
      "vaccination", 
      "herd immunity", 
      "vaccine", 
      "coverage rate", 
      "HK dollars", 
      "adolescent females", 
      "health benefits", 
      "ceiling threshold", 
      "incidence", 
      "HK population", 
      "females", 
      "Hong Kong", 
      "HPV", 
      "ResultsCompared", 
      "dose", 
      "immunity", 
      "rate", 
      "girls", 
      "population", 
      "routines", 
      "program", 
      "impact", 
      "cases", 
      "sensitivity analysis", 
      "analysis", 
      "study", 
      "benefits", 
      "ratio", 
      "Kong", 
      "protection", 
      "threshold", 
      "time horizon", 
      "addition", 
      "strategies", 
      "time", 
      "dollars", 
      "model", 
      "results", 
      "catch", 
      "cost", 
      "discount rate", 
      "capita", 
      "gross domestic product", 
      "products", 
      "perspective", 
      "domestic product", 
      "horizon", 
      "dynamic model"
    ], 
    "name": "The impact and cost-effectiveness of 9-valent human papillomavirus vaccine in adolescent females in Hong Kong", 
    "pagination": "75", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1142712721"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1186/s12962-021-00328-x"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "34801050"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1186/s12962-021-00328-x", 
      "https://app.dimensions.ai/details/publication/pub.1142712721"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2022-05-10T10:32", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20220509/entities/gbq_results/article/article_919.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://doi.org/10.1186/s12962-021-00328-x"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1186/s12962-021-00328-x'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1186/s12962-021-00328-x'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1186/s12962-021-00328-x'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1186/s12962-021-00328-x'


 

This table displays all metadata directly associated to this object as RDF triples.

199 TRIPLES      22 PREDICATES      99 URIs      88 LITERALS      7 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1186/s12962-021-00328-x schema:about anzsrc-for:14
2 anzsrc-for:1402
3 schema:author N0a837aea353648ab874a147c2994c6a9
4 schema:citation sg:pub.10.1186/1471-2334-10-272
5 sg:pub.10.1186/s12879-020-05632-0
6 sg:pub.10.1186/s12916-018-1118-3
7 schema:datePublished 2021-11-20
8 schema:datePublishedReg 2021-11-20
9 schema:description IntroductionIn Hong Kong (HK), a single-cohort vaccination program for 10–12-year-old girls with the 9-valent human papillomavirus (HPV) vaccine (9vHPV; types 6/11/16/18/31/33/45/52/58) has been launched. This study assessed the public health impact and cost-effectiveness of implementing routine 9vHPV vaccination (12-year-olds) with or without catch-up 9vHPV vaccination (13–18-year-olds) in HK.MethodsThe health impact and costs of implementing routine 9vHPV vaccination with or without catch-up vaccination over a 100-year time horizon were evaluated using a validated HPV-type transmission dynamic model adapted to the HK population; analyses were performed from a healthcare payer perspective. Routine vaccination (12-year-old girls) and catch-up vaccination (13–18 years) assumed vaccine coverage rates of 70% (base case) and 30%, respectively. The model also assumed herd immunity, lifelong vaccine protection, a discount rate of 3%, and a cost per dose of HK dollars (HKD) 858 [United States dollars (USD) 110] and HKD 1390 (USD 179) for the 2-valent HPV (2vHPV) and 9vHPV vaccines, respectively. HPV disease-related incidence and the incremental cost-effectiveness ratio (ICER) per quality-adjusted-life-year (QALY) were estimated. Cost-effectiveness was determined at a ceiling threshold of HK dollars (HKD) 382,046 (USD 49,142) or 1.0 times the gross domestic product per capita of HK.ResultsCompared with routine 9vHPV alone, routine plus catch-up 9vHPV is projected to reduce cervical cancer incidence by 3.4%. Routine plus catch-up 9vHPV will also reduce genital warts incident cases for males/females by 2.6%/5.4%. The incremental cost-effectiveness ratios were HKD 29,911 (USD 3847)/quality-adjusted life-year (QALY) for routine plus catch-up 9vHPV versus routine 9vHPV alone and HKD 25,524 (USD 3283)/QALY for routine 9vHPV alone versus screening only. Sensitivity analyses indicated that routine plus catch-up 9vHPV compared with routine 9vHPV alone remained cost-effective at coverage rates of 30% and 90%.ConclusionsThis analysis predicts that the current HK vaccination strategy can be considered cost-effective and will provide maximum health benefit. These results support addition of the routine 9vHPV vaccine with or without catch-up 9vHPV vaccination to the regional vaccination program in HK.
10 schema:genre article
11 schema:inLanguage en
12 schema:isAccessibleForFree true
13 schema:isPartOf N782e3984e84142c189bd8223aac94131
14 Nf464ec8cc007493c902c1a7381f0d1a9
15 sg:journal.1032048
16 schema:keywords ConclusionsThis analysis
17 HK dollars
18 HK population
19 HPV
20 Hong Kong
21 Kong
22 ResultsCompared
23 addition
24 adolescent females
25 analysis
26 benefits
27 cancer incidence
28 capita
29 cases
30 catch
31 ceiling threshold
32 cervical cancer incidence
33 cost
34 cost-effectiveness ratio
35 coverage rate
36 discount rate
37 dollars
38 domestic product
39 dose
40 dynamic model
41 females
42 girls
43 gross domestic product
44 health benefits
45 health impacts
46 healthcare payer perspective
47 herd immunity
48 horizon
49 human papillomavirus vaccine
50 immunity
51 impact
52 incidence
53 incident cases
54 incremental cost-effectiveness ratio
55 lifelong vaccine protection
56 male/female
57 maximum health benefits
58 model
59 papillomavirus vaccine
60 payer perspective
61 perspective
62 population
63 products
64 program
65 protection
66 public health impact
67 rate
68 ratio
69 regional vaccination program
70 results
71 routine vaccination
72 routines
73 sensitivity analysis
74 strategies
75 study
76 threshold
77 time
78 time horizon
79 transmission dynamic model
80 vaccination
81 vaccination program
82 vaccination strategies
83 vaccine
84 vaccine coverage rates
85 vaccine protection
86 schema:name The impact and cost-effectiveness of 9-valent human papillomavirus vaccine in adolescent females in Hong Kong
87 schema:pagination 75
88 schema:productId Nb9dd3c391106497392e2cdd84b0142a5
89 Nc796dc8bb27444fca98df326361cd903
90 Nd1af329ac1ed45e991617297fdc4b3ab
91 schema:sameAs https://app.dimensions.ai/details/publication/pub.1142712721
92 https://doi.org/10.1186/s12962-021-00328-x
93 schema:sdDatePublished 2022-05-10T10:32
94 schema:sdLicense https://scigraph.springernature.com/explorer/license/
95 schema:sdPublisher N34b114a5e5c64163a51bd1883741ad8d
96 schema:url https://doi.org/10.1186/s12962-021-00328-x
97 sgo:license sg:explorer/license/
98 sgo:sdDataset articles
99 rdf:type schema:ScholarlyArticle
100 N0a837aea353648ab874a147c2994c6a9 rdf:first sg:person.01371611151.45
101 rdf:rest N73328def999245a186e99d4718f250bb
102 N0e639da2d7ad4ca782d00f03f82caac0 rdf:first Na0b7d424b20349bd8843b16d5b1a4360
103 rdf:rest Nc3749caefa6642ff884155dca50f5146
104 N34b114a5e5c64163a51bd1883741ad8d schema:name Springer Nature - SN SciGraph project
105 rdf:type schema:Organization
106 N5f5452e46acf45dcb931bd259dff76e5 rdf:first sg:person.011736111537.43
107 rdf:rest N6557a134209c43c5b7bd8948f6f669b4
108 N650d8fb4bba748639158a542528e7c9e rdf:first sg:person.013611671644.98
109 rdf:rest N5f5452e46acf45dcb931bd259dff76e5
110 N6557a134209c43c5b7bd8948f6f669b4 rdf:first sg:person.013153105213.76
111 rdf:rest Nf970732d86da49f981020a32f7b888cd
112 N73328def999245a186e99d4718f250bb rdf:first Nfc392b6d977b4c4e9508600fcf74ce69
113 rdf:rest N0e639da2d7ad4ca782d00f03f82caac0
114 N782e3984e84142c189bd8223aac94131 schema:issueNumber 1
115 rdf:type schema:PublicationIssue
116 Na0b7d424b20349bd8843b16d5b1a4360 schema:affiliation grid-institutes:None
117 schema:familyName Hsu
118 schema:givenName Danny C.
119 rdf:type schema:Person
120 Nb9dd3c391106497392e2cdd84b0142a5 schema:name pubmed_id
121 schema:value 34801050
122 rdf:type schema:PropertyValue
123 Nc3749caefa6642ff884155dca50f5146 rdf:first sg:person.01352415670.11
124 rdf:rest N650d8fb4bba748639158a542528e7c9e
125 Nc796dc8bb27444fca98df326361cd903 schema:name dimensions_id
126 schema:value pub.1142712721
127 rdf:type schema:PropertyValue
128 Nd1af329ac1ed45e991617297fdc4b3ab schema:name doi
129 schema:value 10.1186/s12962-021-00328-x
130 rdf:type schema:PropertyValue
131 Nf464ec8cc007493c902c1a7381f0d1a9 schema:volumeNumber 19
132 rdf:type schema:PublicationVolume
133 Nf970732d86da49f981020a32f7b888cd rdf:first sg:person.0725134162.11
134 rdf:rest rdf:nil
135 Nfc392b6d977b4c4e9508600fcf74ce69 schema:affiliation grid-institutes:None
136 schema:familyName Cheng
137 schema:givenName Sally Shuk Yee
138 rdf:type schema:Person
139 anzsrc-for:14 schema:inDefinedTermSet anzsrc-for:
140 schema:name Economics
141 rdf:type schema:DefinedTerm
142 anzsrc-for:1402 schema:inDefinedTermSet anzsrc-for:
143 schema:name Applied Economics
144 rdf:type schema:DefinedTerm
145 sg:journal.1032048 schema:issn 1478-7547
146 schema:name Cost Effectiveness and Resource Allocation
147 schema:publisher Springer Nature
148 rdf:type schema:Periodical
149 sg:person.011736111537.43 schema:affiliation grid-institutes:grid.417993.1
150 schema:familyName Walia
151 schema:givenName Anuj
152 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.011736111537.43
153 rdf:type schema:Person
154 sg:person.013153105213.76 schema:affiliation grid-institutes:grid.417993.1
155 schema:familyName Saxena
156 schema:givenName Kunal
157 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.013153105213.76
158 rdf:type schema:Person
159 sg:person.01352415670.11 schema:affiliation grid-institutes:None
160 schema:familyName Wong
161 schema:givenName Queenie Wing-Lei
162 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01352415670.11
163 rdf:type schema:Person
164 sg:person.013611671644.98 schema:affiliation grid-institutes:None
165 schema:familyName Pavelyev
166 schema:givenName Andrew
167 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.013611671644.98
168 rdf:type schema:Person
169 sg:person.01371611151.45 schema:affiliation grid-institutes:grid.10784.3a
170 schema:familyName Cheung
171 schema:givenName Tak Hong
172 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01371611151.45
173 rdf:type schema:Person
174 sg:person.0725134162.11 schema:affiliation grid-institutes:grid.417993.1
175 schema:familyName Prabhu
176 schema:givenName Vimalanand S.
177 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0725134162.11
178 rdf:type schema:Person
179 sg:pub.10.1186/1471-2334-10-272 schema:sameAs https://app.dimensions.ai/details/publication/pub.1026945611
180 https://doi.org/10.1186/1471-2334-10-272
181 rdf:type schema:CreativeWork
182 sg:pub.10.1186/s12879-020-05632-0 schema:sameAs https://app.dimensions.ai/details/publication/pub.1134382708
183 https://doi.org/10.1186/s12879-020-05632-0
184 rdf:type schema:CreativeWork
185 sg:pub.10.1186/s12916-018-1118-3 schema:sameAs https://app.dimensions.ai/details/publication/pub.1105932555
186 https://doi.org/10.1186/s12916-018-1118-3
187 rdf:type schema:CreativeWork
188 grid-institutes:None schema:alternateName Global Medical and Scientific Affairs, MSD Asia Ltd, 27/F Lee Gardens Two, 28 Yun Ping Road, Causeway Bay, Hong Kong, People’s Republic of China
189 HCL America, Inc., Sunnyvale, CA, USA
190 schema:name Global Medical and Scientific Affairs, MSD Asia Ltd, 27/F Lee Gardens Two, 28 Yun Ping Road, Causeway Bay, Hong Kong, People’s Republic of China
191 HCL America, Inc., Sunnyvale, CA, USA
192 MRL, Merck & Co., Inc., 2000 Galloping Hill Road, 07033, Kenilworth, NJ, USA
193 rdf:type schema:Organization
194 grid-institutes:grid.10784.3a schema:alternateName Department of Obstetrics and Gynecology, The Chinese University of Hong Kong, Hong Kong, People’s Republic of China
195 schema:name Department of Obstetrics and Gynecology, The Chinese University of Hong Kong, Hong Kong, People’s Republic of China
196 rdf:type schema:Organization
197 grid-institutes:grid.417993.1 schema:alternateName MRL, Merck & Co., Inc., 2000 Galloping Hill Road, 07033, Kenilworth, NJ, USA
198 schema:name MRL, Merck & Co., Inc., 2000 Galloping Hill Road, 07033, Kenilworth, NJ, USA
199 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...